SCHEMBL6322388

SCHEMBL6322388

Fc1cccc(-c2cccc3[nH]ccc23)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ASH1L Q9NR48 2/20 0.59
PIK3CD O00329 3/20 0.56
PIK3CB P42338 2/20 0.52
PIK3CG P48736 1/20 0.51
MAPK14 Q16539 3/20 0.51
TRPA1 O75762 1/20 0.49
CSNK2B P67870 1/20 0.48
CSNK2A1 P68400 1/20 0.48
CDC7 O00311 1/20 0.44
ROCK2 O75116 1/20 0.44
MAP4K4 O95819 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
CDK2 P24941 1/20 0.44
GSK3B P49841 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
CLK4 Q9HAZ1 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
CHEK1 O14757 1/20 0.44
AHR P35869 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6322590 0.88 PIK3CD (0.57) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL10945814 0.83 PIK3CD (0.75) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL6322152 0.82 PIK3CD (0.64) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL18475875 0.81 BRD4 (0.51) ASH1LPIK3CDPIK3CBPIK3CGCSNK2A1
SCHEMBL6321711 0.81 ASH1L (0.60) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL7085001 0.80 PIK3CD (0.53) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL2193011 0.80 PIK3CD (0.70) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL29712113 0.80 PIK3CD (0.70) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL23259083 0.79 ASH1L (0.59) ASH1LPIK3CDPIK3CBPIK3CGMAPK14
SCHEMBL6321811 0.79 CSNK2B (0.62) ASH1LPIK3CDPIK3CBPIK3CGCSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6861418-B2 4-aryl substituted indolinones SUGEN, INC. (US) 2005-03-01 US disclosed
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors SUGEN, INC. 2004-09-23 US disclosed
US-20040157909-A1 4-Aryl substituted indolinones SUGEN, INC. 2004-08-12 US disclosed
US-6677368-B2 4-aryl substituted indolinones SUGEN, INC. 2004-01-13 US disclosed
EP-1349852-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES Sugen, Inc. (US) 2003-10-08 EP disclosed
US-20030069297-A1 4-aryl substituted indolinones SUGEN, INC. 2003-04-10 US disclosed
WO-2002055517-A2 4-(HETERO)ARYL SUBSTITUTED INDOLINONES CUI JINGRONG (US) 2002-07-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069297-A1 4-aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885PIK3CB 275/4885
US-20040157909-A1 4-Aryl substituted indolinones CDK5, CAMK4, TNK2 ASH1L 1883/4885PIK3CD 365/4885PIK3CB 275/4885
US-20040186160-A1 Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors MAP3K15, MAP3K20, MAP3K19 ASH1L 2888/4885PIK3CD 398/4885PIK3CB 433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.